Brokerages Set Exelixis, Inc. (NASDAQ:EXEL) PT at $37.59

Shares of Exelixis, Inc. (NASDAQ:EXEL) have been assigned a consensus rating of “Moderate Buy” from the twenty ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $37.59.

EXEL has been the topic of several recent analyst reports. Stifel Nicolaus upped their price objective on shares of Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research note on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Exelixis in a research note on Thursday, March 27th. Guggenheim reaffirmed a “buy” rating and issued a $42.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. Brookline Capital Management started coverage on Exelixis in a research report on Monday, December 23rd. They set a “buy” rating on the stock. Finally, Wells Fargo & Company reissued a “market outperform” rating on shares of Exelixis in a research note on Thursday.

Insider Activity

In other Exelixis news, CFO Christopher J. Senner sold 29,314 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the completion of the sale, the chief financial officer now directly owns 779,607 shares in the company, valued at $28,174,996.98. This trade represents a 3.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the sale, the executive vice president now directly owns 341,028 shares of the company’s stock, valued at approximately $13,231,886.40. The trade was a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 in the last quarter. Company insiders own 2.85% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Coppell Advisory Solutions LLC acquired a new stake in shares of Exelixis during the fourth quarter valued at about $25,000. Colonial Trust Co SC raised its holdings in Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 765 shares during the last quarter. USA Financial Formulas acquired a new stake in Exelixis during the 4th quarter worth approximately $32,000. Principal Securities Inc. grew its holdings in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 373 shares during the last quarter. Finally, Kestra Investment Management LLC acquired a new position in Exelixis in the 4th quarter valued at approximately $39,000. 85.27% of the stock is owned by institutional investors.

Exelixis Trading Up 0.1 %

Shares of EXEL opened at $36.19 on Tuesday. The stock’s 50 day moving average is $36.37 and its two-hundred day moving average is $34.18. Exelixis has a twelve month low of $20.14 and a twelve month high of $40.02. The firm has a market capitalization of $10.13 billion, a PE ratio of 20.45, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, sell-side analysts predict that Exelixis will post 2.04 EPS for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.